v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Revenue $ 65,200 $ 66,865 $ 202,779 $ 214,804
Operating expenses:        
Cost of revenue 36,826 36,686 113,432 113,635
Selling, general and administrative 39,087 38,864 120,528 112,912
Research and development 4,344 4,347 14,660 12,686
Change in estimated fair value of contingent consideration (178) 2,385 (1,373) 69
Goodwill impairment 154,239 0 154,239 0
Restructuring (4) 0 (1,220) 0
Total operating expenses 234,314 82,282 400,266 239,302
Loss from operations (169,114) (15,417) (197,487) (24,498)
Other income (expense):        
Interest expense (13,634) (11,637) (36,437) (30,492)
Interest income 7,071 7,432 21,367 20,268
Change in payable to related parties pursuant to the Tax Receivable Agreement (39) (1,007) (39) (2,342)
Other income (expense) 72 66 (2,384) (1,386)
Loss before income taxes (175,644) (20,563) (214,980) (38,450)
Income tax expense (benefit) 311 (5,461) (1,853) (10,057)
Net loss (175,955) (15,102) (213,127) (28,393)
Net loss attributable to non-controlling interests (76,917) (8,640) (94,426) (15,323)
Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (99,038) $ (6,462) $ (118,701) $ (13,070)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic (in usd per share) $ (0.70) $ (0.05) $ (0.87) $ (0.10)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., diluted (in usd per share) $ (0.70) $ (0.05) $ (0.87) $ (0.10)
Weighted average number of Class A common shares outstanding, basic (in shares) 141,555 131,930 136,595 131,845
Weighted average number of Class A common shares outstanding, diluted (in shares) 141,555 131,930 136,595 131,845

Source